February 20, 2024
1 min watch
Save
VIDEO: Ruxolitinib ‘pretty good’ long-term option for atopic dermatitis
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Raj Chovatiya, MD, PhD, discussed research into the Janus kinase inhibitor ruxolitinib from the Maui Derm 2024 meeting, examining data into its use in treating atopic dermatitis.
Chovatiya, assistant professor of dermatology at Northwestern University Feinberg School of Medicine, discussed several studies examining itch improvement, pediatric use and long-term data for intermittent use.
“(The data suggests) it’s actually a pretty good long-term therapeutic option, and it really takes a while for people to relapse if they achieve pretty good responses,” Chovatiya said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Chovatiya reports being an advisor, consultant, speaker and/or investigator for AbbVie, Apogee Therapeutics, Arcutis, Argenx, ASLAN Pharmaceuticals, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant, Eli Lilly and Company, FIDE, Galderma, Genentech, GSK, Incyte, Janssen, LEO Pharma, L’Oréal, Nektar Therapeutics, Opsidio, Pfizer Inc., Regeneron, RAPT, Sanofi and UCB.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.